Literature DB >> 10907387

Methylphenidate: its pharmacology and uses.

T D Challman1, J J Lipsky.   

Abstract

Methylphenidate is a commonly used medication in the United States. This central nervous system stimulant has a mechanism of action distinct from that of amphetamine. The Food and Drug Administration has approved methylphenidate for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. Treatment with methylphenidate has been advocated in patients with traumatic brain injury and stroke, cancer patients, and those with human immunodeficiency virus infection. Placebo-controlled trials have documented its efficacy as an adjunctive agent in the treatment of depression and pain. This article reviews the current understanding of the mechanism of action and efficacy of methylphenidate in various clinical conditions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10907387     DOI: 10.4065/75.7.711

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  96 in total

1.  ADHD medications and risk of serious cardiovascular events in young and middle-aged adults.

Authors:  Laurel A Habel; William O Cooper; Colin M Sox; K Arnold Chan; Bruce H Fireman; Patrick G Arbogast; T Craig Cheetham; Virginia P Quinn; Sascha Dublin; Denise M Boudreau; Susan E Andrade; Pamala A Pawloski; Marsha A Raebel; David H Smith; Ninah Achacoso; Connie Uratsu; Alan S Go; Steve Sidney; Mai N Nguyen-Huynh; Wayne A Ray; Joe V Selby
Journal:  JAMA       Date:  2011-12-12       Impact factor: 56.272

Review 2.  Cognitive enhancement as a treatment for drug addictions.

Authors:  Mehmet Sofuoglu; Elise E DeVito; Andrew J Waters; Kathleen M Carroll
Journal:  Neuropharmacology       Date:  2012-06-23       Impact factor: 5.250

3.  Acute and chronic methylphenidate alters prefrontal cortex neuronal activity recorded from freely behaving rats.

Authors:  R Layla Salek; Catherine M Claussen; Adriana Pérez; Nachum Dafny
Journal:  Eur J Pharmacol       Date:  2012-01-25       Impact factor: 4.432

4.  The effects of methylphenidate on cerebral responses to conflict anticipation and unsigned prediction error in a stop-signal task.

Authors:  Peter Manza; Sien Hu; Jaime S Ide; Olivia M Farr; Sheng Zhang; Hoi-Chung Leung; Chiang-shan R Li
Journal:  J Psychopharmacol       Date:  2016-01-11       Impact factor: 4.153

5.  Effects of methylphenidate and bupropion on DHEA-S and cortisol plasma levels in attention-deficit hyperactivity disorder.

Authors:  Moon-Soo Lee; Jae-Won Yang; Young-Hoon Ko; Changsu Han; Seung-Hyun Kim; Min-Soo Lee; Sook-Haeng Joe; In-Kwa Jung
Journal:  Child Psychiatry Hum Dev       Date:  2007-08-31

Review 6.  Methylphenidate and the juvenile brain: enhancement of attention at the expense of cortical plasticity?

Authors:  Kimberly R Urban; Wen-Jun Gao
Journal:  Med Hypotheses       Date:  2013-09-17       Impact factor: 1.538

7.  Neuroprotective effects of various doses of topiramate against methylphenidate-induced oxidative stress and inflammation in isolated rat amygdala: the possible role of CREB/BDNF signaling pathway.

Authors:  Majid Motaghinejad; Manijeh Motevalian; Reza Falak; Mansour Heidari; Mahshid Sharzad; Elham Kalantari
Journal:  J Neural Transm (Vienna)       Date:  2016-09-24       Impact factor: 3.575

8.  Relative lack of cognitive effects of methylphenidate in elderly male volunteers.

Authors:  Danielle C Turner; Trevor W Robbins; Luke Clark; Adam R Aron; Jonathan Dowson; Barbara J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2003-05-07       Impact factor: 4.530

9.  Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine.

Authors:  Ronald Kuczenski; David S Segal
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

10.  Modulation of motorcortical excitability by methylphenidate in adult voluntary test persons performing a go/nogo task.

Authors:  Johannes Buchmann; A Dueck; W Gierow; H Zamorski; S Heinicke; H Heinrich; J Hoeppner; T Klauer; O Reis; F Haessler
Journal:  J Neural Transm (Vienna)       Date:  2009-12-10       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.